Program
Clascoterone
Also written as “Winlevi (clascoterone) 1% cream”, “CB-03-01 cream, 1%” and “Clascoterone 5% solution”.
Its studies are mostly in Acne Vulgaris · Alopecia, led by 4 companies.
Drug pageClascoterone: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cassiopea SpA | 70 open or running | phase 3since Nov 17, 2015 | Nov 17, 2015 | none ahead |
| Sun Pharmaceutical Industriesits history only | 61 open or running | phase 4since Mar 11, 2024 | Mar 11, 2024 | none ahead |
| 3SBioits history only | 32 open or running | phase 3since Apr 30, 2024 | Apr 30, 2024 | Aug 7, 2028phase 3 · NCT07457294 |
| Intrepid Therapeuticsits history only | 30 open or running | phase 2since Jun 27, 2012 | Jun 27, 2012 | none ahead |
Also a collaborator on its studies: Canfield Scientific and ICON Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Cassiopea SpA only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 17, 2015First studies: 2 phase 3 studies in Acne VulgarisFirst studyNCT02608476, NCT02608450
- Feb 10, 2016Phase 3 study in Acne VulgarisNCT02682264 · 609 enrolled · United States, Bulgaria, Georgia and more
- Mar 22, 2016Phase 2 study in Acne VulgarisNCT02720627 · 27 enrolled · United States, Poland
- Jun 18, 2018Phase 1 study in Healthy VolunteersNCT03665194 · 32 enrolled · United Kingdom
- Dec 9, 2018Named clascoteroneINNProposed as its International Nonproprietary Name in WHO's List 120
- Jun 6, 20232 phase 3 studies in AlopeciaNCT05914805, NCT05910450
TargetBeta
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 7 Cassiopea SpA leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05914805Alopecia · United States, Germany, Poland | 3 | Completed | Jul 16, 2025 | 762 |
| NCT05910450Alopecia · United States, Georgia | 3 | Completed | Jan 26, 2026 | 703 |
| NCT03665194Healthy Volunteers · United Kingdom | 1 | Completed | Sep 12, 2018 | 32 |
| NCT02720627Acne Vulgaris · United States, Poland | 2 | Completed | Mar 21, 2018 | 27 |
| NCT02682264Acne Vulgaris · United States, Bulgaria, Georgia and more | 3 | Completed | Aug 31, 2018 | 609 |
| NCT02608476Acne Vulgaris · United States, Bulgaria, Georgia and more | 3 | Completed | Feb 21, 2018 | 732 |
| NCT02608450Acne Vulgaris · United States, Georgia, Ukraine | 3 | Completed | Apr 11, 2018 | 708 |
How it is read
Names in the registry
- “Winlevi (clascoterone) 1% cream”, 3 entries
- “CB-03-01 cream, 1%”, 3 entries
- “Clascoterone 5% solution”, 2 entries
- “cortexolone 17α-propionate”, 2 entries
- “CB-03-01”, 2 entries
Conditions, from the studies’ own filings
- Acne Vulgaris, 15 studies
- Alopecia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.